{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=12", "query": { "condition": "Neuroendocrine Carcinoma", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 946, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:24:16.847Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Adenocarcinoma", "Human Papillomavirus-Related Anal Squamous Cell Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Merkel Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Stage III Merkel Cell Carcinoma AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Pleural Malignant Mesothelioma AJCC v7", "Stage IV Merkel Cell Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IV Pleural Malignant Mesothelioma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-03-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074513" }, { "nct_id": "NCT03685591", "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Prostate Neoplasms", "Neoplasms, Squamous Cell", "Melanoma", "Mesothelioma", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Carcinoma, Renal Cell", "Liver Neoplasms" ], "interventions": [ { "name": "PF-06952229", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-10-04", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685591" }, { "nct_id": "NCT03634982", "title": "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "RMC-4630", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2018-09-28", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2022-09-01", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03634982" }, { "nct_id": "NCT04541108", "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Rilvegostomig", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Sabestomig", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "AZD9592", "type": "BIOLOGICAL" }, { "name": "AZD9592 + Rilvegostomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Volrustomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Sabestomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-07-26", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 9, "location_summary": "Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more", "locations": [ { "city": "Shreveport", "state": "Louisiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541108" }, { "nct_id": "NCT01218555", "title": "Study of Everolimus (RAD001) in Combination With Lenalidomide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Organ Malignancies", "Adenoidcystic Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2010-09-09", "completion_date": "2020-11-05", "has_results": true, "last_update_posted_date": "2022-01-27", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218555" }, { "nct_id": "NCT03304639", "title": "Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Merkel Cell Carcinoma", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Merkel Cell Carcinoma", "Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-06-12", "completion_date": "2026-02-19", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 254, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03304639" }, { "nct_id": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Gastric Cancer", "Stomach Cancer", "Gastroesophageal Junction Cancer", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma", "Uveal Melanoma", "Merkel Cell Carcinoma", "Mesothelioma", "MSI", "Non-small Cell Lung Cancer", "NSCLC", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "RCC", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Mismatch Repair Deficiency" ], "interventions": [ { "name": "INCAGN02390", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-09-24", "completion_date": "2021-08-18", "has_results": false, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 4, "location_summary": "Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntsville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652077" }, { "nct_id": "NCT06060613", "title": "Safety and Efficacy of OBX-115 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tumor Skin", "Metastatic Melanoma", "Melanoma", "Lung Cancer", "Metastatic Lung Cancer", "Non Small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "OBX-115", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Obsidian Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2023-10-25", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 9, "location_summary": "Los Angeles, California • Stanford, California • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06060613" }, { "nct_id": "NCT05064150", "title": "Neuroendocrine Tumors - Patient Reported Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumors", "Gastroenteropancreatic Neuroendocrine Tumor", "Lung Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2539, "start_date": "2022-05-10", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 14, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064150" }, { "nct_id": "NCT05422781", "title": "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Merkel Cell Carcinoma" ], "interventions": [ { "name": "ITI-3000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunomic Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-06-13", "completion_date": "2023-06-27", "has_results": false, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-10-14T09:24:16.847Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05422781" } ] }